# Organon

2021 年从 MSD/默克剥离,Organon 是最大的专注女性健康公司,公布 2025 全年营收 62 亿美元、调整后 EBITDA 19.1 亿美元(利润率 30.7%),拥有产后止血的 Jada 系统与避孕植入体 Nexplanon。

Source: https://cn.bioecon.ru/companies/organon/
Updated: 2026-06-28

- 国家: United States
- 代码: NYSE:OGN

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 生产基地 | 六家生产工厂分别位于比利时、巴西、印度尼西亚、墨西哥、荷兰和英国 | https://www.sec.gov/Archives/edgar/data/1821825/000119312526177473/ars_fy2025.pdf, https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm, https://www.stocktitan.net/sec-filings/OGN/10-k-organon-co-files-annual-report-2594554d2f73.html |
| 认证 | 英国克拉姆灵顿工厂的GMP合规认证 | https://cms.mhra.gov.uk/mhra/gmp/uk-mia-25-insp-gmp-254061-0035h, https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm |
| 监管批准 | 药品和医疗器械须获得FDA及国际监管机构的批准 | https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm, https://www.stocktitan.net/sec-filings/OGN/10-k-organon-co-files-annual-report-2594554d2f73.html |
| 员工人数 | 截至2025年12月31日，全球员工超过10,000人 | https://www.sec.gov/Archives/edgar/data/1821825/000119312526177411/ogn-ogn_proxy_2026_html_only.pdf, https://www.sec.gov/Archives/edgar/data/1821825/000119312526177473/ars_fy2025.pdf, https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm, https://www.stocktitan.net/sec-filings/OGN/10-k-organon-co-files-annual-report-2594554d2f73.html |
| 营收 | 2025全年为$6.216 billion | https://organon2021tf.q4web.com/news/news-details/2026/Organon-Reports-Results-for-the-Fourth-Quarter-and-Full-Year-Ended-December-31-2025/default.aspx, https://www.organon.com/news/organon-reports-results-for-the-fourth-quarter-and-full-year-ended-december-31-2025/, https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm |

独立来源: cms.mhra.gov.uk, sec.gov, stocktitan.net

## 技术

- [FemTech 生物技术与女性健康](https://cn.bioecon.ru/technology/femtech-biotech-womens-health/)